Status of secondary prevention in patients undergoing coronary revascularization.
Allen
J K
JK
Johns Hopkins University, Baltimore, Maryland 21205-2100, USA. jallen@son.jhmi.edu
Blumenthal
R S
RS
Margolis
S
S
Young
D R
DR
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D015906:Angioplasty, Balloon, Coronary; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy*; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D012008:Recurrence; D012307:Risk Factors
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000960:Hypolipidemic Agents; D008055:Lipids; D001241:Aspirin